New research shows that Rytvela, an anti-inflammatory drug candidate, decreased premature birth and infant mortality when administered after the onset of preterm labor in a preclinical mouse model. The current standard treatment for preterm labor, Nifedipine, failed to confer similar benefits.
Continue Reading this article here
